Asiatic acid ameliorates rifampicin‐ and isoniazid‐induced liver injury in vivo by regulating sphingolipid metabolism and mitogen‐activated protein kinase signalling pathways
Basic & Clinical Pharmacology & Toxicology · 2023-10 · 133 (4) · 402-417
DOI: 10.1111/bcpt.13909 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2023-08. Verfasst von Wuchang Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical College, Guangxi Medical University, Nanning, China. Hauptthemen laut MEDLINE: Chemical and Drug Induced Liver Injury, Chronic, Chemical and Drug Induced Liver Injury. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Scientific and Technological Innovation Major Base of Guangxi, Guangxi Key Laboratory for Bioactive Molecules Research and Evaluation.
Abstract (Originalsprache)
In this study, we aimed to determine whether asiatic acid (AA) exerts any therapeutic effects on rifampicin (RFP)‐ and isoniazid (INH)‐induced liver injury and elucidate the underlying mechanisms. Briefly, liver injury in mice was induced via RFP and INH administration. We investigated the effects and potential action mechanisms of AA on liver injury using transcriptomics, metabolomics and various examinations. We found that AA significantly ameliorated the pathological changes in liver tissues and decreased the transaminase activity, inflammation and oxidative stress damage. Transcriptomics revealed 147 differentially expressed genes (DEGs) between the AA and model groups that were enriched in metabolic and mitogen‐activated protein kinase ( MAPK ) signalling pathways. Metabolomics revealed 778 differentially expressed metabolites between the AA and model groups. Furthermore, integrated transcriptomics and metabolomics analyses revealed strong correlations between DEGs and differentially expressed metabolites and indicated that AA regulates the sphingolipid metabolism by inhibiting the expression of delta 4‐desaturase, sphingolipid 1. Experimental results confirmed that AA inhibited the MAPK signalling pathway. In summary, AA inhibits inflammation and oxidative stress damage by regulating the sphingolipid metabolism pathway and blocking the MAPK signalling pathway, thereby relieving the RFP/INH‐induced liver injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical College, Guangxi Medical University, Nanning, China.
- Pharmacy Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
- Pharmacy Department, The People's Hospital of Hezhou, Hezhou, China.
ORCID-Profile: Jinbin Wei
Förderung
- National Natural Science Foundation of China
- Scientific and Technological Innovation Major Base of Guangxi
- Guangxi Key Laboratory for Bioactive Molecules Research and Evaluation
- Guangxi Beibu Gulf Marine Biomedicine Precision Development and High-value Utilization Engineering Research Center
- Guangxi Health Commission Key Laboratory of Basic Research on Antigeriatric Drugs
Zitieren
APA
Zhu, W., Su, H., Wei, Y., Huang, Y., Chen, S., Shi, Y., Long, Y., Qiu, Y., & Wei, J. (2023). Asiatic acid ameliorates rifampicin‐ and isoniazid‐induced liver injury in vivo by regulating sphingolipid metabolism and mitogen‐activated protein kinase signalling pathways. Basic & Clinical Pharmacology & Toxicology, 133(4), 402-417. https://doi.org/10.1111/bcpt.13909
Vancouver
Zhu W, Su H, Wei Y, Huang Y, Chen S, Shi Y, et al. Asiatic acid ameliorates rifampicin‐ and isoniazid‐induced liver injury in vivo by regulating sphingolipid metabolism and mitogen‐activated protein kinase signalling pathways. Basic & Clinical Pharmacology & Toxicology. 2023;133(4):402-417. doi:10.1111/bcpt.13909
BibTeX
@article{Zhu2023,
author = {Zhu, Wuchang and Su, Hongmei and Wei, Yuanyuan and Huang, Yushen and Chen, Siyun and Shi, Yanxia and Long, Yan and Qiu, Yue and Wei, Jinbin},
title = {Asiatic acid ameliorates rifampicin‐ and isoniazid‐induced liver injury in vivo by regulating sphingolipid metabolism and mitogen‐activated protein kinase signalling pathways},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2023},
volume = {133},
number = {4},
pages = {402--417},
doi = {10.1111/bcpt.13909}
}
EUVIMED